Skip to Content

What does Ocaliva treat?

Answers (1)

Official Answer by 1 Jun 2016

Ocaliva (generic name: obeticholic acid) was given accelerated FDA approval in May 2016 and is combined with ursodeoxycholic acid (UDCA) in adults with an inadequate UDCA response or as the only treatment in adults unable to tolerate UDCA. Ocaliva is a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC), previously known as biliary cirrhosis. FXR is a nuclear receptor expressed in the liver and intestine and a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways.

PBC is a rare liver disease that primarily results from autoimmune destruction of the bile ducts that transport bile acids out of the liver, resulting in cholestasis. Cholestasis occurs when the flow of bile from the liver decreases. Symptoms of cholestasis include itching, dark-colored urine, stomach pain, yellowing of the eyes or skin (jaundice), and pale-colored stools.

Ocaliva is the first new treatment for PBC in nearly 20 years. free discount card

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of drug is Vitrakvi (larotrectinib)?

Updated 7 days ago 1 answerFAQ by

What is the difference between Truxima and Rituxan?

Updated 7 days ago 1 answerFAQ by

What type of leukemia is Xospata (gilteritinib) used to treat?

Updated 7 days ago 1 answerFAQ by

What is the difference between Tolsura and Sporanox?

Updated 6 days ago 1 answerFAQ by

What is Firdapse (amifampridine) used to treat?

Updated 13 hours ago 1 answerFAQ by